Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk reports positive data from long-term Fiasp study

Novo Nordisk reports positive data from long-term Fiasp study

13th September 2017

Novo Nordisk has announced new clinical trial data demonstrating the long-term benefits offered by its type 1 diabetes therapy Fiasp.

The ultra-fast-acting mealtime insulin was recently evaluated in a study showing that Fiasp was able to improve overall blood sugar and post-meal sugar control over 52 weeks, compared to Novo Nordisk's conventional insulin aspart therapy NovoRapid.

Fiasp maintained the significant improvements in overall blood sugar control previously seen in a shorter-term 26-week study, while the safety profile of the product was also confirmed.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "Fiasp delivers benefits for people with diabetes, helping them to achieve better post-meal and overall blood sugar control."

The product was designed to bring post-meal sugar levels down more effectively than conventional rapid-acting insulins, which are not as fast as the speed of the natural physiological insulin response.

Fiasp was approved by the European Commission earlier this year and is currently under regulatory review in more than ten countries.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801839832-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.